Clinical Trial Comparing Gemcitabine and Vandetanib Therapy With Gemcitabine Alone in Pancreatic Carcinoma

Study ID
NCT01601808

Study type
Interventional

Study phase
Phase 2

Study status
Unknown status

Trial Acronym

ViP

Trial Summary

ViP is a double blinded clinical trial which will compare gemcitabine and vandetanib chemotherapy with gemcitabine alone in patients with locally advanced or metastatic pancreatic carcinoma.

More informations

Trial Starting Date

Oct 31,2011

Requirements

Gender All
Minimum age 18 Years
Maximum age N/A

Enrollement Limit

120